Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Atebimetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial

    26 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/26/3157242/0/en/Immuneering-to-Discuss-Recently-Announced-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-Monday-September-29-20.html

    GLOBENEWSWIRE
    26 Sep 2025
    Share Share
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x

    25 Sep 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months

    BIOSPACE
    25 Sep 2025
    Share Share
    Immuneering's Ph 2a Update on Atebimetinib + mGnP for Cancer
    Immuneering's Ph 2a Update on Atebimetinib + mGnP for Cancer

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3147620/0/en/Immuneering-to-Announce-Updated-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-September-25.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share